Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of SENS-401 for prevention of cisplatin-induced ototoxicity in adults with malignancy
MOH_2022-10-04_012089Phase 2Active, not recruiting
- Sponsor
- Sensorion
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of arazasetron besylate in cisplatin-induced ototoxicity (2 arms), sponsored by Sensorion. Started Apr 2022; status: active, not recruiting.
02
Drugs
arazasetron besylate
03
Conditions
cisplatin-induced ototoxicity
Beyond the preview
Go deeper on MOH_2022-10-04_012089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-10-04_012089.